OpenLB
Open Library of Bioscience
Advanced Search
Immunology letters
12, 2020;228 83-85.

Azithromycin and glucosamine may amplify the type 1 interferon response to RNA viruses in a complementary fashion.

James J DiNicolantonio, Jorge Barroso-Aranda, Mark F McCarty
Author Information
  1. James J DiNicolantonio: Mid America Heart Institute, Kansas City, MO, United States.
  2. Jorge Barroso-Aranda: Clinica Libre de Adicciones, Tijuana, B.C, Mexico.
  3. Mark F McCarty: Catalytic Longevity Foundation, United States. Electronic address: markfmccarty@gmail.com.
PMID: 33002511 DOI: 10.1016/j.imlet.2020.09.008

Abstract

Previous research demonstrates that, in clinically relevant concentrations, azithromycin can boost the ability of RNA viruses to induce type 1 interferon by amplifying the expression and virally-mediated activation of MDA5. O-GlcNAcylation of MAVS, a down-stream target of MDA5, renders it more effective for type 1 interferon induction. High-dose glucosamine administration up-regulates O-GlcNAcylation by increasing the cellular pool of UDP-N-acetylglucosamine. Hence, it is proposed that joint administration of azithromycin and high-dose glucosamine, early in the course of RNA virus infections, may interact in a complementary fashion to aid their control by enhancing type 1 interferon induction.

Keywords

Azithromycin Glucosamine IRF-3 MAVS MDA5 Type 1 interferon

References

  1. Arzneimittelforschung. 1991 May;41(5):542-5 [PMID: 1898426]
  2. J Clin Invest. 1995 Jul;96(1):132-40 [PMID: 7615783]
  3. Am J Respir Cell Mol Biol. 2013 Dec;49(6):1110-9 [PMID: 23898954]
  4. Eur J Epidemiol. 2012 Aug;27(8):593-603 [PMID: 22828954]
  5. Am J Trop Med Hyg. 2020 Aug;103(2):561-563 [PMID: 32588812]
  6. Front Immunol. 2018 Aug 28;9:1957 [PMID: 30210502]
  7. Immunol Res. 2012 Sep;53(1-3):58-77 [PMID: 22434514]
  8. Crit Rev Biochem Mol Biol. 2016 May-Jun;51(3):150-61 [PMID: 26806492]
  9. J Clin Invest. 1995 Dec;96(6):2792-801 [PMID: 8675649]
  10. Arthritis Res Ther. 2012 Jun 27;14(3):R155 [PMID: 22734582]
  11. Am J Clin Nutr. 2010 Jun;91(6):1791-800 [PMID: 20410091]
  12. Int Heart J. 2017 Dec 12;58(6):926-932 [PMID: 29151484]
  13. Nat Chem Biol. 2008 Aug;4(8):483-90 [PMID: 18587388]
  14. Eur Respir J. 2010 Sep;36(3):646-54 [PMID: 20150207]
  15. J Clin Lab Anal. 2020 Oct;34(10):e23562 [PMID: 32893398]
  16. Oncotarget. 2017 May 9;8(19):31601-31611 [PMID: 28415826]
  17. PLoS One. 2015 Feb 26;10(2):e0117534 [PMID: 25719429]
  18. Eur Respir J. 2015 Feb;45(2):428-39 [PMID: 25359346]
  19. Travel Med Infect Dis. 2020 Jul - Aug;36:101791 [PMID: 32593867]
  20. Osteoarthritis Cartilage. 2011 Apr;19(4):375-80 [PMID: 21251987]
  21. Cancer Causes Control. 2011 Sep;22(9):1333-42 [PMID: 21706174]
  22. J Mol Biol. 2008 Feb 15;376(2):526-40 [PMID: 18164316]
  23. Antimicrob Agents Chemother. 2019 Sep 16;: [PMID: 31527024]
  24. Int J Mol Med. 2008 Sep;22(3):317-23 [PMID: 18698490]
  25. Sci Rep. 2016 Jun 28;6:28698 [PMID: 27350308]
  26. Vet Microbiol. 2017 Nov;211:36-42 [PMID: 29102119]
  27. Nat Commun. 2017 Jul 12;8(1):69 [PMID: 28701733]
  28. Virol J. 2005 Aug 22;2:69 [PMID: 16115318]
  29. Front Immunol. 2019 Feb 21;10:275 [PMID: 30846987]
  30. AAPS J. 2020 Jun 12;22(4):86 [PMID: 32533263]
  31. J Antimicrob Chemother. 2016 Oct;71(10):2767-81 [PMID: 27494903]
  32. Cell Rep. 2019 Aug 27;28(9):2386-2396.e5 [PMID: 31461653]
  33. Cancer Causes Control. 2013 Jun;24(6):1137-46 [PMID: 23529472]
  34. Ups J Med Sci. 2011 Nov;116(4):227-37 [PMID: 22066971]
  35. Int J Antimicrob Agents. 2020 Dec;56(6):106214 [PMID: 33122096]
  36. Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):1309-1320 [PMID: 29622561]
  37. Prog Cardiovasc Dis. 2020 May - Jun;63(3):383-385 [PMID: 32061635]

MeSH Term

Animals
Antiviral Agents
Azithromycin
Drug Therapy, Combination
Glucosamine
Host-Pathogen Interactions
Humans
Interferon Type I
RNA Virus Infections
RNA Viruses

Chemicals

Antiviral Agents
Interferon Type I
Azithromycin
Glucosamine
Journal Article Review
Article has an altmetric score of 4

Word Cloud

Created with Highcharts 10.0.01interferontypeRNAMDA5glucosamineazithromycinvirusesO-GlcNAcylationMAVSinductionadministrationmaycomplementaryfashionAzithromycinPreviousresearchdemonstratesclinicallyrelevantconcentrationscanboostabilityinduceamplifyingexpressionvirally-mediatedactivationdown-streamtargetrenderseffectiveHigh-doseup-regulatesincreasingcellularpoolUDP-N-acetylglucosamineHenceproposedjointhigh-doseearlycoursevirusinfectionsinteractaidcontrolenhancingamplifyresponseGlucosamineIRF-3Type

Similar Articles

Cited By